The Texas Biomedical Research Institute in San Antonio has applied for a patent for a genetically-engineered vaccine strategy to prevent HIV infection that targets the outer layers of body structures that are the first sites of contact with the virus. Designed to be a single dose and last a lifetime, the vaccine will lead to the continual production of disease-fighting cells without being eliminated by the immune system. Another feature of the vaccine system is that it could be adapted for use against other infections...
More...
More...